drugset / Trial / NCT00207116
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer
Timeline
- Start
- 2005-09
- Primary completion
- 2006-03
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |